Thyroid-Associated Ophthalmopathy Clinical Trial
Official title:
A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy.
To investigate the efficacy,safety and tolerability of 99Tc-MDP in comparison to Methylprednisolone, in the treatment of participants suffering from active moderate to severe TAO.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02693808 -
New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression
|
N/A | |
Completed |
NCT01599273 -
Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections
|
Phase 4 | |
Completed |
NCT01579539 -
The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy
|
Phase 3 | |
Recruiting |
NCT02203682 -
Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy
|
Phase 2 | |
Completed |
NCT01868997 -
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
|
Phase 2 | |
Terminated |
NCT00288522 -
Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
|
Phase 2 | |
Recruiting |
NCT04936854 -
Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease
|
Phase 2 | |
Completed |
NCT00595335 -
Trial of Rituximab for Graves' Ophthalmopathy
|
Phase 2/Phase 3 |